epoetin alfa
Selected indexed studies
- Epoetin alfa biosimilar (HX575): A review of 15 years' post-approval clinical experience. (Crit Rev Oncol Hematol, 2023) [PMID:36481307]
- Epoetin-alfa induced pruritic maculopapular eruption: Case report and literature review. (Asian Pac J Allergy Immunol, 2023) [PMID:32563229]
- Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols. (Leuk Res, 2019) [PMID:31005849]
_Worker-drafted node — pending editorial review._
Connections
epoetin alfa is a side effect of
Sources
- Epoetin alfa biosimilar (HX575): A review of 15 years' post-approval clinical experience. (2023) pubmed
- Epoetin-alfa induced pruritic maculopapular eruption: Case report and literature review. (2023) pubmed
- Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols. (2019) pubmed
- Epoetin alfa as a supportive measure in hematologic malignancies. (2002) pubmed
- Epoetin alfa therapy for patients with hematologic malignancies and mild anemia. (2003) pubmed
- Pharmacist-driven epoetin alfa-epbx dosing for hospitalized patients. (2023) pubmed
- Epoetin alfa improves quality of life in patients with cancer: results of metaanalysis. (2004) pubmed
- Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia. (2006) pubmed
- Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis. (2010) pubmed
- Epoetin alfa in cancer patients: evidence-based guidelines. (2001) pubmed